Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Vitamin C sensitizes triple negative breast cancer to PI3K inhibition therapy.
Mustafi S, Camarena V, Qureshi R, Sant DW, Wilkes Z, Bilbao D, Slingerland J, Kesmodel SB, Wang G. Mustafi S, et al. Among authors: slingerland j. Theranostics. 2021 Jan 20;11(8):3552-3564. doi: 10.7150/thno.53225. eCollection 2021. Theranostics. 2021. PMID: 33664847 Free PMC article.
The Major Pre- and Postmenopausal Estrogens Play Opposing Roles in Obesity-Driven Mammary Inflammation and Breast Cancer Development.
Qureshi R, Picon-Ruiz M, Aurrekoetxea-Rodriguez I, Nunes de Paiva V, D'Amico M, Yoon H, Radhakrishnan R, Morata-Tarifa C, Ince T, Lippman ME, Thaller SR, Rodgers SE, Kesmodel S, Vivanco MDM, Slingerland JM. Qureshi R, et al. Cell Metab. 2020 Jun 2;31(6):1154-1172.e9. doi: 10.1016/j.cmet.2020.05.008. Cell Metab. 2020. PMID: 32492394 Free article.
DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer.
Kurani H, Razavipour SF, Harikumar KB, Dunworth M, Ewald AJ, Nasir A, Pearson G, Van Booven D, Zhou Z, Azzam D, Wahlestedt C, Slingerland J. Kurani H, et al. Among authors: slingerland j. Clin Cancer Res. 2022 May 2;28(9):1948-1965. doi: 10.1158/1078-0432.CCR-21-1299. Clin Cancer Res. 2022. PMID: 35135840 Free PMC article.
PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.
Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM. Wander SA, et al. Among authors: slingerland jm. Breast Cancer Res Treat. 2013 Apr;138(2):369-81. doi: 10.1007/s10549-012-2389-6. Epub 2013 Feb 21. Breast Cancer Res Treat. 2013. PMID: 23430223 Free PMC article.
Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM. Azzam DJ, et al. Among authors: slingerland jm. EMBO Mol Med. 2013 Oct;5(10):1502-22. doi: 10.1002/emmm.201302558. Epub 2013 Aug 27. EMBO Mol Med. 2013. PMID: 23982961 Free PMC article.
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM. Simpkins F, et al. Among authors: slingerland jm. Clin Cancer Res. 2012 Nov 1;18(21):5911-23. doi: 10.1158/1078-0432.CCR-12-1257. Epub 2012 Aug 15. Clin Cancer Res. 2012. PMID: 22896656 Free PMC article.
150 results